A RETROSPECTIVE CROSS-SECTIONAL STUDY TO ASSESS THE TREATMENT PATTERN AMONG THALASSEMIA PATIENT IN A TERTIARY CARE HOSPITAL; A SINGLE CENTRAL STUDY
Main Article Content
Keywords
Thalassemia, Deferiprone, Deferasirox, Desferoxamine, Holy Family Hospital, Treatment
Abstract
Background: Thalassemia characterized by a defect in the synthesis of haemoglobin (Hb) or its globin subunits. This study was conducted to evaluate the treatment pattern of thalassemia in public hospital.
Methodology: Retrospective study was conducted to assess thalassemia treatment pattern in Holy Family Hospital Rawalpindi, from September 2022 to December 2022. Total 430 registered thalassemia patients were included in this study. Data were collected and analyzed by using software SPSS version 24.
Results: Participants included in this study have 1:1 of male and female. Among 430 participants, the majority of participants belonged to <3 age (years) group 219(50.9%). 322 (74.9%) belong to the rural areas, 11 (2.6%) were from elite background. 24 (5.6%) among partcipants belong to capital and 352(81.90) belong to Punjab. It was noticed that the consanguinity of the thalassemia was 306 (71.2%) of total cases, due to first cousin marriages. Type of thalassemia which was diagnosed in patients have different types in which, 31 (7.2%) were diagnosed with β-thalassemia minor, 308 (71.6%) β-thalassemia major, 85 (19.8%) homozygous β-thalassemia, 5 (1.2%) hemolytic anemia and 1 (0.2%) intermedia thalassemia. Among total 430 thalassemia patients, 427 (99.3%) received blood transfusion and 3 (0.7%) didn’t. 150 (34.9%) receive iron chelation therapy and 280 (65.1%) didn’t. 35 (8.1%) administered the iron antidote desferoxamine and 395 (91.9%) didn’t. 312 (72.6%) took iron chelator deferasirox and 118 (27.4%) didn’t. 85 (19.8%) were advised folic acid, 81 (18.8%) were advised calcium supplement, 10 (2.3%) thalassemia patient taking vitamin supplement, Deferiprone is an iron chelator that was 17 (4.0%) prescribed to the patients, 2 (0.5%) were taking ceclor (antibiotic), 2 (0.5%) advised Hepa-Merz which is used as a supportive therapy in liver disease, 1 (0.2%) patient taking Aceclofenac which is a non-steroidal agent,1(0.2%) patient was taking Ondansetron, 2 (0.5%) were advised Hydroxyurea, used in chronic myeloid leukemia (CML).
Conclusion: Each patient should have a medical file with precise documentation of blood transfusion requirements, iron chelation therapy requirements and CBC, haemophilia, electrophoresis monitoring, and transfusion reactions. Patients and relatives should be informed about thalassemia. Before getting married, couples should do a quick blood test to check for thalassemia to see if they are carriers or not.
References
2. Ansari, S. H., Shamsi, T. S., Ashraf, M., Bohray, M., Farzana, T., Khan, M. T., Perveen, K., Erum, S., Ansari, I., Nadeem, M., Ahmed, M., & Raza, F. (2011). Molecular epidemiology of β-thalassemia in Pakistan: far reaching implications. Int J Mol Epidemiol Genet, 2(4), 403-408.
3. Asif, N., & Hassan, K. (2014). Prevention of beta thalassemia in Pakistan. J Islam Med Dent Coll, 3(2), 46-47.
4. Bajwa, H., & Basit, H. (2019). Thalassemia.
5. Black, M. L., Sinha, S., Agarwal, S., Colah, R., Das, R., Bellgard, M., & Bittles, A. H. (2010). A descriptive profile of β-thalassaemia mutations in India, Pakistan and Sri Lanka. Journal of Community Genetics, 1(3), 149-157. https://doi.org/10.1007/s12687-010-0026-9
6. Cappellini, M.-D., Cohen, A., Porter, J., Taher, A., & Viprakasit, V. (2014). Guidelines for the management of transfusion dependent thalassaemia (TDT). Thalassaemia International Federation Nicosia, Cyprus.
7. Cappellini, M. D., Cohen, A., Piga, A., Bejaoui, M., Perrotta, S., Agaoglu, L., Aydinok, Y., Kattamis, A., Kilinc, Y., & Porter, J. (2006). A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood, 107(9), 3455-3462.
8. Chatterjee, R., & Bajoria, R. (2010). Critical appraisal of growth retardation and pubertal disturbances in thalassemia. Annals of the New York Academy of Sciences, 1202(1), 100-114.
9. Davis, B. A., & Porter, J. B. (2002). Results of long term iron chelation treatment with deferoxamine. Iron Chelation Therapy, 91-125.
10. Fica, S., Albu, A., Vladareanu, F., Barbu, C., Bunghez, R., Nitu, L., & Marinescu, D. (2005). Endocrine disorders in beta-thalassemia major: cross-sectional data. ACTA ENDOCRINOLOGICA-BUCHAREST-, 1(2), 201.
11. Forget, B. G., & Bunn, H. F. (2013). Classification of the disorders of hemoglobin. Cold Spring Harbor perspectives in medicine, 3(2), a011684.
12. Galanello, R., & Origa, R. (2010). Beta-thalassemia. Orphanet Journal of Rare Diseases, 5(1), 11. https://doi.org/10.1186/1750-1172-5-11
13. Haddad, A., Tyan, P., Radwan, A., Mallat, N., & Taher, A. (2014). β-thalassemia intermedia: a bird’s-eye view. Turkish Journal of Hematology, 31(1), 5.
14. Kadhim, K. A., Baldawi, K. H., & Lami, F. H. (2017). Prevalence, incidence, trend, and complications of thalassemia in Iraq. Hemoglobin, 41(3), 164-168.
15. Khalid, N., Noreen, K., Qureshi, F., & Mahesar, M. (2019). Knowledge of thalassemia and consanguinity: A multicenter hospital based retrospective cohort study from metropolitan city of Karachi, Pakistan. The Professional Medical Journal, 26, 1580-1586. https://doi.org/ 10.29309/TPMJ/2019.26.09.168
16. Lasco, A., Morabito, N., Gaudio, A., Buemi, M., Wasniewska, M., & Frisina, N. (2001). Effects of hormonal replacement therapy on bone metabolism in young adults with beta-thalassemia major. Osteoporosis International, 12, 570-575.
17. Lucarelli, G., & Gaziev, J. (2015). Hematopoietic cell transplantation for thalassemia. Thomas’ Hematopoietic Cell Transplantation: Stem Cell Transplantation, 1, 842-854.
18. Olivieri, N., Freedman, M., Koren, G., Hermann, C., Bentur, Y., Chung, D., Klein, J., Louis, P. S., Templeton, D., & McClelland, R. (1990). Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. The Lancet, 336(8726), 1275-1279.
19. Origa, R., Galanello, R., Ganz, T., Giagu, N., Maccioni, L., Faa, G., & Nemeth, E. (2007). Liver iron concentrations and urinary hepcidin in β-thalassemia. Haematologica, 92(5), 583-588.
20. Pennell, D. J., Berdoukas, V., Karagiorga, M., Ladis, V., Piga, A., Aessopos, A., Gotsis, E. D., Tanner, M. A., Smith, G. C., & Westwood, M. A. (2006). Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood, 107(9), 3738-3744.
21. Piga, A. (2017). Impact of bone disease and pain in thalassemia. Hematology 2014, the American Society of Hematology Education Program Book, 2017(1), 272-277.
22. Rachmilewitz, E. A., & Giardina, P. J. (2011). How I treat thalassemia. Blood, The Journal of the American Society of Hematology, 118(13), 3479-3488.
23. Rund, D., & Rachmilewitz, E. (2005). β-Thalassemia. New England Journal of Medicine, 353(11), 1135-1146.
24. Shahid, S., Nadeem, M., Zahid, D., Hassan, J., Ansari, S., & Shamsi, T. (2017). Alpha thalassemia deletions found in suspected cases of beta thalassemia major in Pakistani population. Pakistan journal of medical sciences, 33(2), 411.
25. Unissa, R., Monica, B., Konakanchi, S., Darak, R., Keerthana, S. L., & Kumar, S. A. (2018). Thalassemia: a review. Asian Journal of Pharmaceutical Research, 8(3), 195-202.
26. Weatherall, D., & Clegg, J. B. (2001). Inherited haemoglobin disorders: an increasing global health problem. Bulletin of the World Health Organization, 79(8), 704-712.
27. Barua, T., Das, A. K., Sultana, R., Das, D., & Arju, M. A. C. (2020). Socio-demographic profile of patients admitted in Thalassemia care center of Chattogram Maa Shishu-O-General Hospital. Chattagram Maa-O-Shishu Hospital Medical College Journal, 19(1), 33-37.
28. Bennett, R. L., Hudgins, L., Smith, C. O., & Motulsky, A. G. (1999). Inconsistencies in genetic counseling and screening for consanguineous couples and their offspring: the need for practice guidelines. Genetics in Medicine, 1(6), 286-292.
29. Fibach, E., & Rachmilewitz, E. (2008). The role of oxidative stress in hemolytic anemia. Current molecular medicine, 8(7), 609-619.
30. Gafer, A., Alrabeei, N. A., Al-Awar, M. S., Edrees, W. H., & Alyafrosi, O. A. H. (2023). Socio-demographic Profile of Patients Admitted in Thalassemia Center, Sana, a, Yemen. Al-Razi University Journal for Medical Sciences, 7(1).
31. Hossain, M. S., Raheem, E., Sultana, T. A., Ferdous, S., Nahar, N., Islam, S., Arifuzzaman, M., Razzaque, M. A., Alam, R., & Aziz, S. (2017). Thalassemias in South Asia: clinical lessons learnt from Bangladesh. Orphanet journal of rare diseases, 12(1), 1-9.
32. Jafroodi, M., Davoudi-Kiakalayeh, A., Mohtasham-Amiri, Z., Pourfathollah, A. A., & Haghbin, A. (2015). Trend in prevalence of hepatitis C virus infection among β-thalassemia major patients: 10 years of experience in Iran. International journal of preventive medicine, 6.
33. Maatook, M. A., Mohammed, K. A., & Afat, A. M. (2015). The socio-demographic profile of thalassemia in Basrah. Med J Babylon, 3, 670â.
34. Moirangthem, A., & Phadke, S. R. (2018). Socio-demographic profile and economic burden of treatment of transfusion dependent thalassemia. The Indian Journal of Pediatrics, 85, 102-107.
35. Olivieri, N., Freedman, M., Koren, G., Hermann, C., Bentur, Y., Chung, D., Klein, J., Louis, P. S., Templeton, D., & McClelland, R. (1990). Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. The Lancet, 336(8726), 1275-1279.
36. Olivieri, N. F., & Brittenham, G. M. (1997). Iron-chelating therapy and the treatment of thalassemia. Blood, The Journal of the American Society of Hematology, 89(3), 739-761.
37. Sattari, M., Sheykhi, D., Nikanfar, A., Pourfeizi, A. H., Nazari, M., Dolatkhah, R., & Mashayekhi, S. (2019). The financial and social impact of thalassemia and its treatment in Iran. Pharmaceutical sciences, 18(3), 171-176.
38. Viprakasit, V., Lee-Lee, C., Chong, Q. T., Lin, K.-H., & Khuhapinant, A. (2009). Iron chelation therapy in the management of thalassemia: the Asian perspectives. International journal of hematology, 90, 435-445.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Alia Yousaf
Department of pharmacy, University of Lahore
Aqna Malik
Department of Pharmacy, University of Chenab, Gujrat.
Asim Raza
Assistant Professor (Epidemiology and Biostatistics), School of Allied Health Sciences, CMH, Lahore Medical College and Institute of Dentistry
Iram Iqbal
Department of Pharmacy, The University of Lahore
Maham Irshad
Department of Pharmacy, The University of Lahore
Dr. Ashfaq Ul Hassan (Pharm-D) M.Phil.
Department of Pharmacy, University of Chenab, Gujrat. Social Security Hospital Gujrat
Muhammad Zafar Siddiq
Department of Pharmacy, The University of Lahore